Preventive treatment with topiramate enhances the quality of life of patients with migraine;El tratamiento preventivo con topiramato mejora la calidad de vida de los pacientes con migraña

Revista de Neurologia

Volumn 43, Issue 5, 2006, Pages 259-263

  Medrano, Vicente ^a   Sempere, A P ^b   Morera Guitart, J ^c   Fernandez Izquierdo S ^a   Espinosa Martinez J ^d  

^a HOSPITAL GENERAL DE ELDA   (Spain)

^b HOSPITAL VEGA BAJA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Headache; HIT 6; Migraine; Neuromodulator; Preventive treatment; Side effects; Topiramate

Indexed keywords

TOPIRAMATE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; FRUCTOSE; NEUROPROTECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; NEUROLOGY; OBSERVATIONAL STUDY; PARESTHESIA; PATIENT SATISFACTION; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; SIDE EFFECT; TREATMENT FAILURE; VOMITING; WEIGHT REDUCTION; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTICONVULSANTS; FEMALE; FRUCTOSE; HUMANS; MIDDLE AGED; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 35348818068     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4305.2005595     Document Type: Article

References (24)

1. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In Silbertein SD, Lipton RB, Dalesio DJ, eds. Wolff's headache and other head pain. 7 ed. New York: Oxford University Press; 2001. p. 121-246.
2. Silberstein SD. Migraine: preventive treatment. Neurología 2004; 19 (Suppl 3): 49-52.
3. Morera J, Mas G. Nuevos tratamientos preventivos de la migraña continua neurológica: cefalea. Barcelona: Ars Medica; 2004. p. 73-83.
4. León-Sarmiento FE, Martínez M, García I, Prada LJ, Gutiérrez CI, Ávila C, et al. Migraña y MIDAS (MIDASELA) en trabajadores hospitalarios colombianos. Rev Neurol 2003; 36: 412-7.
5. Pascual-Lozano AM, Láinez-Andrés JM. Cuestionario MIDAS: evaluación de la discapacidad en pacientes migrañosos. Rev Neurol 2004; 38: 898.
6. Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005; 45 (Suppl 1): S66-73.
7. Aurora SK, Welch KM. Brain excitability in migraine: evidence from transcranial magnetic stimulation studies. Curr Opin Neurol 1998; 11: 205-9.
8. Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine. CNS Drugs 2002; 16: 611-34.
9. Bigal ME, Lipton RB, Krymchantowski AV. The medical management of migraine. Am J Ther 2004; 11: 130-40.
10. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanisms of action. Epilepsia 2000; 41: 3-9.
11. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine. Neurology 2003; 60 (Suppl 1): S238-9.
12. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmit J, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965-73.
13. Silberstein SD, Neto W, Schmitt J, Jacobs D, for the MIGR-001 study group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-5.
14. Diener HC, Tfelt-Hansen P, Dahlof C, Lainez MJ, Sandrini G, Wang SJ, et al, MIGR-003 Study Group. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propanolol as an active control. J Neurol 2004; 251: 943-50.
15. Pascual J, Sánchez del Río M, Mateos V, Láinez JM, Hernández-Gallego J, Leira R, et al. Topiramate for patients with refractory migraine: an observational, multicenter study in Spain. Neurología 2003; 18: 364-7.
16. Gracia-Naya M, Latorre Jiménez A. Valoración de la efectividad del topiramato en el tratamiento preventivo de la migraña. Estudio observacional de una serie consecutiva de pacientes. Neurología 2005; 20: 225-31.
17. Bayliss MS, Dewey JF, Dunlap I, Batenhorst AS, Cady R, Diamond, et al. A study of the feasibility of Internet administration of a computerized health survey: the Headache Impact Test (HIT). Qual Life Res 2003; 12: 953-61.
18. Kosinski M, Bayliss MS, Bjorner JB, Wave JE Jr, Garber WH, Batenhorst AS, et al. A six-item short-form survey for measuring headache impact test: the HIT-6. Qual Life Res 2003; 12: 963-74.
19. Bayliss MS, Bjorner JB, Kosinski, Dahlöf CGH, Dowson A, Cady RK, et al. Development of HIT-6, a paper-based short form for measuring headache impact. In Olesen J, Seteiner TJ, Lipton RB, eds. Frontiers in headache research. Reducing the burden of headache. New York: Oxford University Press; 2003. p. 386-90.
20. Gandek B, Alaconque J, Uzun V, Andrew-Hobbs M. Translating the short-form Headache Impact Test (HIT-6) in 27 countries: methodological and conceptual issues. Qual Life Res 2003; 12: 975-9.
21. De Diego EV, Lanteri-Minet M. Recognition and management of migraine in primary care: influence of functional impact measured by Headache Impact Test (HIT). Cephalagia 2004; 25: 184-90.
22. Nachit-Ouinekh F, Dartigues JF, Henry P, Becg JP, Chastan G, Lemaire N, Hasnaoui EI. Use of the Headache Impact Test (Hit-6) in general practice: relationship with quality of life and severity. Eur J Neurol 2005; 12: 189-93.
23. Young W, Hulihan J, Wu SC. Characterization and time course of parestesia associated with topiramate: data from double-blind, placebo-controlled studies of topiramate in migraine prevention. Annual Meeting of the American Headache Society. Vancouver, Canadá; 10-13 de junio de 2004.
24. Adelman J, Láinez MJA, Jacobs D, Neto W, Shi Y. Analysis of safety data obtained from over 1,500 patients receiving topiramate for migraine prevention. Annual Meeting of the American Headache Society. Vancouver, Canadá; 10-13 de junio de 2004.